Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kymera Therapeutics Inc | KYMR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 33.76 | 04:09:40 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 33.76 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.60 - 45.31 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 33.76 | USD |
Kymera Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.06B | 61.11M | - | 78.59M | -146.96M | -2.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kymera Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KYMR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 35.72 | 37.32 | 33.17 | 35.00 | 504,561 | -1.96 | -5.49% |
| 1 Month | 41.00 | 41.89 | 33.17 | 37.46 | 494,807 | -7.24 | -17.66% |
| 3 Months | 30.48 | 45.31 | 29.75 | 38.10 | 666,247 | 3.28 | 10.76% |
| 6 Months | 11.86 | 45.31 | 9.60 | 27.83 | 818,526 | 21.90 | 184.65% |
| 1 Year | 35.34 | 45.31 | 9.60 | 25.73 | 656,171 | -1.58 | -4.47% |
| 3 Years | 38.37 | 69.12 | 9.60 | 31.43 | 574,834 | -4.61 | -12.01% |
| 5 Years | 32.92 | 91.92 | 9.60 | 32.89 | 516,082 | 0.84 | 2.55% |
Kymera Therapeutics Description
| Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. |
